Patents by Inventor Albert S. Baldwin

Albert S. Baldwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating muscular wasting diseases using NF-KB activation inhibitors
    Patent number: 9173920
    Abstract: Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment for a muscular wasting disease, an NF-?B activation inhibitor capable of blocking the activation of NF-?B.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: November 3, 2015
    Assignee: TheraLogics, Inc.
    Inventors: Denis C. Guttridge, Albert S. Baldwin
  • METHODS OF TREATING MUSCULAR WASTING DISEASES USING NF-KB ACTIVATION INHIBITORS
    Publication number: 20140005127
    Abstract: Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment for a muscular wasting disease, an NF-?B activation inhibitor capable of blocking the activation of NF-?B.
    Type: Application
    Filed: April 22, 2013
    Publication date: January 2, 2014
    Applicant: THERALOGICS, INC.
    Inventors: Denis C. Guttridge, Albert S. Baldwin
  • COMPOSITIONS AND METHODS FOR TREATING AN ACTIVATED B-CELL DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20130338080
    Abstract: The invention relates to compositions and methods for treating an activated B-Cell Diffuse Large B-Cell Lymphoma (ABC-DLBCL). Specifically, the invention relates to treating ABC-DLBCL by administering an NF-?B Essential Modulator (NEMO) Binding Domain (NBD) peptide or a mimetic thereof that inhibits NF-?B activation.
    Type: Application
    Filed: May 21, 2013
    Publication date: December 19, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Nicola MASON, Michael May, Albert S. Baldwin
  • Methods of treating muscular wasting diseases using NF-?B activation inhibitors
    Patent number: 8426355
    Abstract: Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment for a muscular wasting disease, an NF-?B activation inhibitor capable of blocking the activation of NF-?B.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: April 23, 2013
    Assignee: TheraLogics, Inc.
    Inventors: Denis C. Guttridge, Albert S. Baldwin
  • Use of NF-B inhibition in combination therapy for cancer
    Patent number: 7700545
    Abstract: The use of NF-?B inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: April 20, 2010
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Albert S. Baldwin, James C. Cusack, Marty W. Mayo, Cun-Yu Wang
  • Use of NF-?B inhibition in combination therapy for cancer
    Patent number: 7700073
    Abstract: The use of NF-?B inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: April 20, 2010
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Albert S. Baldwin, James C. Cusack, Marty W. Mayo, Cun-Yu Wang
  • Use NF-B inhibition in combination therapy for cancer
    Patent number: 7700543
    Abstract: The use of NF-?B inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described. When chemotherapeutic compounds and radiation activate NF-?B within cells, the cells are more resistant to the cytotoxic effects of these treatments. Inhibition of NF-?B activation is disclosed to provide a method to improve the efficacy of these cancer therapies.
    Type: Grant
    Filed: November 2, 2004
    Date of Patent: April 20, 2010
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Albert S. Baldwin, James C. Cusack, Marty W. Mayo, Cun-Yu Wang
  • Use of NF-&kgr;B inhibition in combination therapy for cancer
    Patent number: 6831057
    Abstract: The use of NF-&kgr;B inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: December 14, 2004
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Albert S. Baldwin, James C. Cusack, Marty W. Mayo, Cun-Yu Wang
  • Nuclear factors associated with transcriptional regulation
    Publication number: 20040214757
    Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transcription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.
    Type: Application
    Filed: January 4, 2002
    Publication date: October 28, 2004
    Inventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. LeBowitz, Albert S. Baldwin, Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
  • Methods for preventing GVHD
    Publication number: 20040166095
    Abstract: Methods are provided for administering alloreactive T cells to transplant recipients such that the risk of graft-versus-host disease is reduced.
    Type: Application
    Filed: February 25, 2003
    Publication date: August 26, 2004
    Inventors: Bruce R. Blazar, Matthew J. O'Shaughnessy, Christine Vogtenhuber, Jonathan S. Serody, Albert S. Baldwin, Brian Poligone
  • Nuclear factors associated with transcriptional regulation
    Patent number: 6410516
    Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 25, 2002
    Assignees: President & Fellows of Harvard College, Massachusetts Institute of Technology, Whitehead Instittue for Biomedical Research
    Inventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. Lebowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
  • USE OF NF-KB INHIBITION IN COMBINATION THERAPY FOR CANCER
    Publication number: 20020068690
    Abstract: The use of NF-&kgr;B inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.
    Type: Application
    Filed: October 28, 1997
    Publication date: June 6, 2002
    Inventors: ALBERT S. BALDWIN, JAMES C. CUSACK, MARTY W. MAYO, CUN-YU WANG
  • Nuclear factors associated with transcriptional regulation
    Patent number: 6150090
    Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 21, 2000
    Assignees: Massachusetts Institute of Technology, Whitehead Institute, President and Fellows of Harvard College
    Inventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. LeBowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
  • Inhibitor of NF-.kappa.B transcriptional activator and uses thereof
    Patent number: 6001582
    Abstract: Compositions involving I.kappa.B (i.e., inhibitor of Nuclear Factor-.kappa.B or NF-.kappa.B) and methods of using the same are described that have applications for the identification of prophylactics or therapeutics for the treatment of diseases resulting from altered gene expression, including genes that encode cytokines or related molecules.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 14, 1999
    Assignee: The University of North Carolina
    Inventors: John Stephen Haskill, Albert S. Baldwin, Jr., Peter Ralph
  • Method of identifying a chemical that alters dissociation of an NF-KB/IKB complex
    Patent number: 5846714
    Abstract: Compositions and methods of using the same are described that have applications for the identification of prophylactics or therapeutics for the treatment of diseases resulting from altered gene expression, including genes that encode cytokines or related molecules.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 8, 1998
    Assignees: Chiron Corporation, Unversity of North Carolina
    Inventors: John Stephen Haskill, Albert S. Baldwin, Jr., Peter Ralph
  • DNA and expression vector encoding I.kappa.B Protein
    Patent number: 5830756
    Abstract: Compositions and methods of using the same are described that have applications for the identification of prophylactics or therapeutics for the treatment of diseases resulting from altered gene expression, including genes that encode cytokines or related molecules.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 3, 1998
    Assignees: Chiron Corporation, University of North Carolina
    Inventors: John Stephen Haskill, Albert S. Baldwin, Jr., Peter Ralph
  • Nuclear factors associates with transcriptional regulation
    Patent number: 5804374
    Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: September 8, 1998
    Assignees: Massachusetts Insti. Technology, Whitehead Insti., Pres. and Fellow of Harvard College
    Inventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. LeBowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis